Metavant Sciences
  • Contact

NEWS

Mar 06
0

Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences

By Uday Suresh | RVT-1502

LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases SAN DIEGO (March 6, 2018) – Ligand…

Read More
Feb 12
0

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

By Uday Suresh | Imeglimin

Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million (approximately €486 million), and…

Read More
  • Contact


  • Privacy Policy
  • Terms of Use

© 2022 Metavant Sciences.

  • Contact